May 2025 in “Acta Dermato Venereologica” This study found that individuals with hospital-treated alopecia areata in Denmark had increased standardized incidence rates of serious infections, herpes zoster infections, lymphoma, cardiovascular events, and death compared to the age- and sex-matched general population.
January 2018 in “Przegla̧d dermatologiczny” This research review discusses the potential link between androgenetic alopecia and increased cardiovascular risk but does not report any new experimental findings.
September 2023 in “Journal of the American Academy of Dermatology” This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.
1 citations
,
October 2025 in “Frontiers in Cardiovascular Medicine” This review examines AAS-related deaths and finds that anabolic-androgenic steroid abuse may lead to severe cardiac abnormalities, contributing to fatal arrhythmias and sudden cardiac death in young athletes and bodybuilders.
5 citations
,
December 2021 in “Scientific Reports” In this study, researchers found that in mice, gonadal hormones and biological sex do not affect the expression of SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in the respiratory tract, regardless of disease state.
658 citations
,
June 2003 in “Endocrine reviews” This review discusses the role of androgens in the progression of cardiovascular disease and explores novel therapeutic targets without reporting new clinical results.
12 citations
,
June 2023 in “Journal of trace elements in medicine and biology” This study identified dose levels of selenium that can produce toxicity, noting that doses as low as 2-3 µg Se/kg bw/day can lead to adverse effects, and a human mortality study linked 300 µg/day consumption to increased death risk.
418 citations
,
June 2003 in “Endocrine Reviews” This review discusses the relationship between polycystic ovary syndrome and cardiovascular risk, noting a possible adverse impact on risk profiles and subclinical atherosclerosis but no clear increase in premenopausal cardiovascular events; it presents no new clinical results.
150 citations
,
October 2012 in “Clinical Endocrinology” In this retrospective cohort study, women with polycystic ovary syndrome showed high incidence and age-specific prevalence rates of type 2 diabetes, myocardial infarction, and angina, particularly in those over 65.
April 2016 in “JAMA Dermatology” Acne is not a key diagnostic feature for PCOS, postadolescent men with acne may have insulin resistance, melanoma patients often have few moles, tumor size in CSCC indicates higher risk of serious outcomes, and hidradenitis suppurativa is linked to higher risk of heart problems and death.
This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
69 citations
,
October 2014 in “PubMed” This article reviews the various uses and chemical constituents of Rosmarinus officinalis, a common herb used for conditions affecting multiple bodily systems, but presents no new experimental findings.
June 2024 in “Current Developments in Nutrition” This study indicates that DH-AVAs, when used alongside AVAs, may serve as effective biomarkers for assessing whole grain oat intake due to their longer absorption and presence in plasma.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses Hutchinson-Gilford Progeria Syndrome, its symptomatology, and the progress in developing treatment strategies, emphasizing that while a cure remains elusive, advances in understanding the disease's molecular mechanisms show promise for future approaches.
48 citations
,
January 2011 in “Circulation” This report from the American Heart Association highlights that while death rates from cardiovascular diseases have declined significantly, the overall burden of these diseases remains high in the U.S.
January 2023 in “ALEXMED ePosters (Online)” This study observed that alopecia areata patients had higher levels of cardiac Troponin I compared to individuals with androgenic alopecia and healthy controls, suggesting potential cardiac health implications.
278 citations
,
August 2004 in “Best Practice & Research in Clinical Obstetrics & Gynaecology” This article reviews the updated ESHRE/ASRM criteria for diagnosing polycystic ovary syndrome, emphasizing the need for continued research and collaboration, but reports no new clinical results.
17 citations
,
February 2004 in “PubMed” This review discusses symptom-driven treatment approaches for PCOS, focusing on ovulation induction, androgen reduction, and weight management, and reports recent advances like recombinant FSH and GnRH-agonist protocols without providing new clinical results.
2 citations
,
March 2016 in “InnovAiT” This article discusses the signs, symptoms, and associated risks of polycystic ovary syndrome, without providing new clinical results; it emphasizes the link between being overweight and increased metabolic risks.
July 2025 in “SKIN The Journal of Cutaneous Medicine” This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.
January 2024 in “American journal of clinical dermatology” This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.
26 citations
,
July 2003 in “Journal of Cutaneous Medicine and Surgery” This study found that topical minoxidil solution is a safe treatment for androgenetic alopecia, with no increase in cardiovascular events or adverse pregnancy outcomes observed.
January 1989 in “Side effects of drugs annual” This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.
6 citations
,
May 2008 in “Current Opinion in Oncology” This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.
November 2009 in “Cambridge University Press eBooks” This article notes that hair restoration surgery generally has a complication rate of less than 1%, but highlights rare instances of serious cardiovascular events.
12 citations
,
July 2019 in “The Aging Male” This article summarizes data showing that numerous health issues more commonly affect men than women in the U.S., yet men's health receives significantly less attention in biomedical research.
1 citations
,
September 2016 in “British Journal of Dermatology” Women with aging signs and heart issues have higher hair loss risk, which may predict shorter lifespan and affect attractiveness.
October 2008 in “Clin-alert” This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.
11 citations
,
March 2019 in “EMBO molecular medicine” This paper reviews the role of endoplasmic reticulum stress and the unfolded protein response in Hutchinson-Gilford progeria syndrome-related atherosclerosis, especially in vascular smooth muscle cells, but reports no clinical findings; intervention in these pathways is suggested as a potential therapeutic strategy.